An interventional study of Mediterranean diet lessons program and Physical activity in Major Depressive Disorder (MDD), sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli. Recruiting at 2 sites in Italy. Open to participants aged 55 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Depressive Disorder, Major with a site in Italy — 16 open to participants now, 18 under way, 6 of them phase 3. Depressive Disorder, Major · Italy.
Among the 50 studies in Depressive Disorder, Major with a site in Italy, this one is the 28th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2026, is one of 6 with no phase, reaches primary completion later than 11 of the 17 other live ones, and was the 42nd registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →16 of the 50 studies in Depressive Disorder, Major with a site in Italy are open now. Recruiting first, the newest first:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Sites in Italy, Germany, Spain
Ages up to 45 · Healthy volunteers
Janssen Research & Development, LLC · Sites in Italy, United States, Brazil and 4 more countries
Ages 12–17
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 50–80
Neurocrine Biosciences · Sites in Italy, United States, Australia and 8 more countries
Ages 18+
Università Vita-Salute San Raffaele · Sites in Italy
Ages 18–70
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 55 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 80 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 348 across the 39 interventional studies, 350 across the 11 observational. Of the 29 that completed or were terminated, 15 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 50 have an industry lead sponsor. The 10 most frequent:
IRCCS Centro San Giovanni di Dio Fatebenefratelli is the lead sponsor of 36 studies on the registry; 13 are open to participants now.
IRCCS Centro San Giovanni di Dio Fatebenefratelli has 3 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
5 of the studies in Depressive Disorder, Major with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06559306Phase 3Janssen Research & Development, LLCPhase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | 2026-12-30 |
| NCT06550037Alessio FasanoOptimize and Predict Antidepressant Efficacy for Patient With MDD Using Multi-omics Analysis and AI-predictive Tool | 2027-04 |
| NCT07009223IRCCS Centro San Giovanni di Dio FatebenefratelliLifestyle Interventions to Prevent Cognitive Deficits in Subjects With Depressive Symptoms: From Mechanisms to Clinical Practice | 2027-04 |
| NCT06990035IRCCS Centro San Giovanni di Dio FatebenefratelliImplementation of a Multiple Intervention to Promote Healthy Lifestyles in Patients With Depression | 2027-08 |
| NCT07932093Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoUnveiling Maternal-fetal BRAin-body Interactions in Pregnant WOmen Affected by Depression | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 50 studies in Depressive Disorder, Major with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial aims to investigate whether an integrative approach combining education on the Mediterranean diet and physical activity (PA) can significantly reduce depressive symptomatology in individuals with major depressive disorder. The study will evaluate changes in depressive symptoms and assess biological modulations, including alterations in the gut microbiota and inflammatory markers, resulting from the PA intervention.
Participants will be randomized into two arms: the active control group will attend a series of lessons focused on the Mediterranean diet, while the experimental group will participate in the same dietary lessons combined with a structured PA program of 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mediterranean diet lessons program
Behavioral: Mediterranean diet lessons program
Physical activity program
Behavioral: Mediterranean diet lessons program · Behavioral: Physical activity
Participants will attend five one-hour lessons delivered by qualified professionals to learn about foods that have a positive impact on cognitive function and how to incorporate them into their dietary regimen.
Participants will undergo a 12-week physical exercise program guided by specified personal trainers.
MADR Scale for Depression
The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered scale designed to assess the severity of depressive symptoms. It consists of 10 items, each rated on a scale from 0 to 6, yielding a total score ranging from 0 to 60. Higher scores indicate greater severity of depression, meaning a worse clinical outcome.
Time frame: Baseline (day 1); Week 6 (up to 6 weeks, mid-treatment); Week 12 (up to 12 weeks, end of treatment).
Beck Depression Inventory - II
The Beck Depression Inventory (BDI) is a self-report questionnaire used to assess the presence and severity of depressive symptoms. It comprises 21 items, each rated on a scale from 0 to 3, resulting in a total score ranging from 0 to 63. Higher scores reflect more severe depressive symptoms, indicating a worse clinical outcome.
Time frame: Baseline (day 1); Week 6 (up to 6 weeks, mid-treatment); Week 12 (up to 12 weeks, end of treatment).
Zung Self-Rating Depression Scale
The Zung Self-Rating Depression Scale (ZRS) is a self-administered questionnaire designed to assess the level of depressive symptoms in individuals. It consists of 20 items, each rated on a scale from 1 to 4, based on how often symptoms are experienced. The raw total score ranges from 20 to 80, which is often converted to an index score (ranging from 25 to 100) by multiplying the raw score by 1.25. Higher scores indicate more severe depression
Time frame: Baseline (day 1); Week 6 (up to 6 weeks, mid-treatment); Week 12 (up to 12 weeks, end of treatment).
Personal and Social Performance Scale
The Personal and Social Performance Scale (PSP) is a clinician-rated instrument used to assess personal and social functioning in individuals with mental disorders. The total score ranges from 1 to 100, with higher scores indicating better functioning and a more favorable clinical outcome.
Time frame: Baseline (day 1); Week 6 (up to 6 weeks, mid-treatment); Week 12 (up to 12 weeks, end of treatment).
World Health Organization Quality of Life - Bref
The WHOQOL-BREF is a self-report questionnaire developed by the WHO to assess quality of life across multiple domains. It contains 26 items rated on a 5-point Likert scale. Higher scores indicate a better quality of life, reflecting a more favorable outcome.
Time frame: Baseline (day 1); Week 6 (up to 6 weeks, mid-treatment); Week 12 (up to 12 weeks, end of treatment).
Immunitary-related factors levels
Plasma/serum levels of cytokines
Time frame: Baseline (day 1); Week 12 (up to 12 weeks, end of treatment).
Gut Microbiome Composition
Time frame: Baseline (day 1); Week 12 (up to 12 weeks, end of treatment).
Started Jan 2026 (actual). Primary completion is estimated for Aug 2027, 19 months after the start.
Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 19 months is below that.
Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: start Jul 2025 → Jan 2026, primary completion Feb 2026 → Aug 2027 and completion Feb 2026 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Centro San Giovanni di Dio Fatebenefratelli